Benjamin Edwards Inc Cellectis S.A. Transaction History

Benjamin Edwards Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$18.19 - $33.25 $10,295 - $18,819	-566 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$15.87 - $31.64 $2,729 - $5,442	-172 Reduced 23.31%	566 $15,000
Q3 2020 Nov 16, 2020	SELL	$15.7 - $20.84 $188 - $250	-12 Reduced 1.6%	738 $14,000
Q2 2020 Aug 14, 2020	BUY	$8.21 - $21.02 $2,257 - $5,780	275 Added 57.89%	750 $13,000
Q1 2020 May 07, 2020	BUY	$7.81 - $18.82 $171 - $414	22 Added 4.86%	475 $4,000
Q4 2019 Feb 06, 2020	BUY	$9.73 - $19.31 $116 - $231	12 Added 2.72%	453 $8,000
Q3 2019 Nov 05, 2019	SELL	$10.15 - $16.89 $40 - $67	-4 Reduced 0.9%	441 $5,000
Q2 2019 Aug 08, 2019	BUY	$14.6 - $20.6 $2,190 - $3,090	150 Added 50.85%	445 $7,000
Q1 2019 May 15, 2019	BUY	$15.53 - $19.75 $4,581 - $5,826	295 New	295 $5,000

10.8M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $71M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Benjamin Edwards Inc, based on Form 13F filings with the SEC.

Stay updated on Benjamin Edwards Inc with notifications on news.